GSK Advances Pipeline with $2.2B RAPT Buy, Continues Share Repurchases
GSK shares gained after finalizing its $2.2 billion purchase of RAPT Therapeutics, acquiring a Phase IIb food allergy candidate, and disclosed further share repurchases as part of an ongoing program.
Markets
